Baxter submits MAA for hemophilia B product

Baxter International Inc. (NYSE:BAX) submitted an MAA to EMA for Rixubis ( BAX 326) for the treatment and prophylaxis of bleeding in hemophilia B patients. Baxter already markets the recombinant Facto...